BITTER MELON and DIABETES

DEFINITION:
Bitter melon is an annual plant growing to 2 m tall. It is cultivated in Asia, Africa, South America, and India and is considered a tropical fruit. The plant has lobed leaves, yellow flowers, and edible (but bitter-tasting), orange-yellow fruit. The unripe fruit is green and is cucumber-shaped with bumps on its surface. The parts used include the fruit, leaves, seeds, and seed oil.

USAGE
The plant has been used as a traditional medicine in China, India, Africa, and the southeastern US. The plant has been used in the treatment of diabetes symptoms.

Folk wisdom has it that bitter melon helps to prevent or counteract type-II diabetes. A recent scientific study at JIPMER, India has proved that bitter melon increases insulin sensitivity. Also, in 2007, the Philippine Department of Health issued a circular stating that bitter melon, as a scientifically validated herbal medicinal plant, can lower elevated blood sugar levels. The study revealed that a 100 milligram per kilo dose per day is comparable to 2.5 milligrams of the anti-diabetes drug Glibenclamide taken twice per day. Bitter melon is sold in the Philippines as a food supplement and marketed under the trade name Charantia. Charantia capsules and tea are being exported to the United States, Canada, Europe, Mexico, Japan, Korea, and parts of the Middle East.
Bitter melon transformed into capsule form and sold as a food supplement.

Bitter Melon contains four very promising bioactive compounds. These compounds activate a protein called AMPK, which is well known for regulating fuel metabolism and enabling glucose uptake, processes which are impaired in diabetics. "We can now understand at a molecular level why bitter melon works as a treatment for diabetes," said David James, director of the diabetes and obesity program at the Garvan Institute of Medical Research in Sydney. "By isolating the compounds we believe to be therapeutic, we can investigate how they work together in our cells."

Bitter melon contains a lectin that has insulin-like activity. The insulin-like bioactivity of this lectin is due to its linking together insulin receptors. This lectin lowers blood glucose concentrations by acting on peripheral tissues and, similar to insulin's effects in the brain, suppressing appetite. This lectin is likely a major contributor to the hypoglycemic effect that develops after eating bitter melon and why it may be a way of managing adult-onset diabetes. Lectin binding is non-protein specific, and this is likely why bitter melon has been credited with immunostimulatory activity - by linking receptors that modulate the immune system, thereby stimulating said receptors.

For availability and more information
call
+254 722 559 484
or e-mail johnmwega@gmail.com